68738 Federal Register / Vol. 71, No.
228 / Tuesday, November 28, 2006 / Rules and Regulations
Security Officer, HS–1/Forrestal
Building’’.
■ c. Paragraphs (d) and (e) by removing
‘‘DOE Director of Security Affairs’’ and
adding in their place ‘‘Chief Health,
Safety and Security Officer’’.
■ d. Paragraph (f) by removing ‘‘DOE
Director of Security Affairs’’’ and adding
in its place ‘‘Chief Health, Safety and
Security Officer’s’’.
PART 1046—PHYSICAL PROTECTION
OF SECURITY INTERESTS
■ 145. The authority citation for part
1046 continues to read as follows:
Authority: Sec. 2201, Pub. L. 83–703, 68
Stat. 919 (42 U.S.C. 2201 et seq.); sec. 7151,
Pub. L. 95–91, 91 Stat. 565 (42 U.S.C. 7101
et seq.).
§ 1046.3 [Amended]
■ 146. Section 1046.3 is amended in the
definition of ‘‘Designated physician’’ by
removing ‘‘Medical Director, Office of
Operational and Environmental Safety,
Headquarters’’ and adding in its place
‘‘Director, Office of Health and Safety’’
and by removing ‘‘Medical’’ in the
second sentence.
Appendix A to Subpart B of Part 1046
[Amended]
■ 147. Appendix A is amended in:
■ a. Section B.(9) by removing ‘‘Director
of Safeguards and Security,
Headquarters,’’ and adding in its place
‘‘Chief Health, Safety and Security
Officer’’.
■ b. Section G.(1)(e) by removing
‘‘Director of Safeguards and Security,
DOE Headquarters,’’ and adding in its
place ‘‘Chief Health, Safety and Security
Officer’’.
■ c. Section J.(5) by removing ‘‘Director
of Safeguards and Security, DOE
Headquarters’’ and adding in its place
‘‘Chief Health, Safety and Security
Officer’’.
Appendix B to Subpart B of Part 1046
[Amended]
■ 148. Appendix B is amended in:
■ a. Section B.(1) by removing ‘‘Central
Training Academy (CTA)’’ and adding
in its place ‘‘National Training Center,’’
and by removing ‘‘Director, Office of
Safeguards and Security’’ and adding in
its place ‘‘Chief Health, Safety and
Security Officer’’.
■ b. Section B.(9)(b) is amended by
removing ‘‘DOE Operations Office’’ and
adding in its place ‘‘DOE field office’’.
■ c. Section B.(9)(g) by removing ‘‘Office
mstockstill on PROD1PC61 with RULES
of Safeguards and Security (SA–10)’’
and adding in its place ‘‘Chief Health,
Safety and Security Officer’’.
■ d. Section B.(9)(i) by removing
‘‘Central Training Academy’’ and
VerDate Aug<31>2005 13:50 Nov 27, 2006 Jkt 211001
adding in its place ‘‘National Training
Center’’.
PART 1049—LIMITED ARREST
AUTHORITY AND USE OF FORCE BY
PROTECTIVE FORCE OFFICERS OF
THE STRATEGIC PETROLEUM
RESERVE
■ 149. The authority citation for part
1049 continues to read as follows:
Authority: 42 U.S.C. 7101 et seq.
§ 1049.8 [Amended]
■ 150. Section 1049.8(a) is amended by
removing ‘‘Department of Energy Office
of Safeguards and Security’’ and adding
in its place ‘‘Chief Health, Safety and
Security Officer’’.
[FR Doc. E6–20104 Filed 11–27–06; 8:45 am]
BILLING CODE 6450–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 520
Oral Dosage Form New Animal Drugs;
Neomycin
AGENCY: Food and Drug Administration,
HHS.
ACTION: Final rule.
SUMMARY: The Food and Drug
Administration (FDA) is amending the
animal drug regulations to reflect
approval of an abbreviated new animal
drug application (ANADA) filed by
Sparhawk Laboratories, Inc. The
ANADA provides for use of neomycin
sulfate oral solution in livestock for the
treatment and control of bacterial
enteritis.
DATES: This rule is effective November
28, 2006.
FOR FURTHER INFORMATION CONTACT: John
K. Harshman, Center for Veterinary
Medicine (HFV–104), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 301–827–0169, e-
mail: john.harshman@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Sparhawk
Laboratories, Inc., 12340 Santa Fe Trail
Dr., Lenexa, KS 66215, filed ANADA
200–379 for the use of Neomycin Liquid
in cattle, swine, sheep, and goats for the
treatment and control of bacterial
enteritis. Sparhawk Laboratories, Inc.’s
Neomycin Liquid is approved as a
generic copy of Pharmacia &Upjohn
Co.’s BIOSOL Liquid, sponsored by
Pharmacia & Upjohn Co., a Division of
Pfizer, Inc., under ANADA 200–113.
The ANADA is approved as of October
PO 00000 Frm 00012 Fmt 4700 Sfmt 4700
24, 2006, and the regulations in 21 CFR
520.1484 are amended to reflect the
approval. The basis of approval is
discussed in the freedom of information
summary.
In accordance with the freedom of
information provisions of 21 CFR part
20 and 21 CFR 514.11(e)(2)(ii), a
summary of safety and effectiveness
data and information submitted to
support approval of this application
may be seen in the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852, between 9
a.m. and 4 p.m., Monday through
Friday.
FDA has determined under 21 CFR
25.33(a)(1) that this action is of a type
that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
This rule does not meet the definition
of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because
it is a rule of ‘‘particular applicability.’’
Therefore, it is not subject to the
congressional review requirements in 5
U.S.C. 801–808.
List of Subjects in 21 CFR Part 520
Animal drugs.
■ Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs and redelegated to
the Center for Veterinary Medicine, 21
CFR part 520 is amended as follows:
PART 520—ORAL DOSAGE FORM
NEW ANIMAL DRUGS
■ 1. The authority citation for 21 CFR
part 520 continues to read as follows:
Authority: 21 U.S.C. 360b.
§ 520.1484 [Amended]
■ 2. In paragraph (b)(3) of § 520.1484,
add ‘‘058005,’’ in numerical sequence.
Dated: November 16, 2006.
Bernadette Dunham,
Deputy Director, Office of New Animal Drug
Evaluation, Center for Veterinary Medicine.
[FR Doc. E6–20126 Filed 11–27–06; 8:45 am]
BILLING CODE 4160–01–S
E:\FR\FM\28NOR1.SGM 28NOR1